What is 64Cu-DOTA-TLX592 used for?

64Cu-DOTA-TLX592 is indicated for Neuroendocrine tumors.

Who makes 64Cu-DOTA-TLX592?

64Cu-DOTA-TLX592 is developed by Telix Pharmaceuticals (Innovations) Pty Limited.

What development phase is 64Cu-DOTA-TLX592 in?

64Cu-DOTA-TLX592 is in Phase 1.

Last reviewed 2026-04-23 · How we verify

64Cu-DOTA-TLX592

Telix Pharmaceuticals (Innovations) Pty Limited · Phase 1 active Small molecule

Somatostatin receptor targeting

Somatostatin receptor targeting Used for Neuroendocrine tumors.

At a glance

Generic name	64Cu-DOTA-TLX592
Also known as	64Cu-TLX592
Sponsor	Telix Pharmaceuticals (Innovations) Pty Limited
Drug class	Somatostatin receptor targeting agent
Target	Somatostatin receptor
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 1

Mechanism of action

64Cu-DOTA-TLX592 is a radioligand that targets somatostatin receptors, allowing for imaging and treatment of neuroendocrine tumors.

Approved indications

Neuroendocrine tumors

Common side effects

No common side effects on file.

Key clinical trials

64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

64Cu-DOTA-TLX592 CI brief — competitive landscape report
64Cu-DOTA-TLX592 updates RSS · CI watch RSS
Telix Pharmaceuticals (Innovations) Pty Limited portfolio CI